ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pertuzumab

Also written as “Pertuzumab”, “Pertuzumab IV” and “Perjeta”.

Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Prostatic Neoplasms, led by 6 companies.

Drug pagePertuzumab: every studyMany companies study it; this page follows only the 46 they lead. All 156 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 13, 201546 company-led studies, 3 open or runningNext primary completion: Mar 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche411 open or runningphase 4since May 13, 2015Nov 15, 2001Mar 28, 2027phase 3 · NCT02320435
Cinnagenits history only10 open or runningphase 3since Jun 22, 2021Jun 22, 2021none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since Nov 25, 2022Nov 25, 2022none ahead
Mabscaleits history only11 open or runningphase 1since Apr 11, 2023Apr 11, 2023none ahead
Sarah Cannon Research Instituteits history only10 open or runningphase 2since Aug 27, 2014Aug 27, 2014none ahead
Zydus Lifesciencesits history only10 open or runningphase 3since Feb 26, 2022Feb 26, 2022none ahead

Also a collaborator on its studies: Daiichi Sankyo and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 25 studies since Nov 15, 2001.

  1. Dec 16, 2014Phase 3 study in Solid TumorsNCT02320435 · 154 enrolled · Brazil, China, Costa Rica and more
  2. May 13, 2015Phase 4 study in Breast NeoplasmsNCT02445586 · 52 enrolled · India
  3. Jun 5, 20152 phase 2 studiesNCT02480010, NCT02491892
  4. Jul 2, 20153 phase 1 studiesNCT02490475, NCT02494596, NCT02507375
  5. Aug 10, 2015Phase 2 study in Breast NeoplasmsNCT02536339 · 40 enrolled · United States
  6. Oct 23, 2015Phase 3 study in Breast NeoplasmsNCT02586025 · 329 enrolled · China, Korea, Republic of, Taiwan and more
  7. Mar 29, 2016Phase 1 study in Breast NeoplasmsNCT02738970 · 88 enrolled · New Zealand
  8. Sep 7, 2016Phase 3 study in Breast NeoplasmsNCT02896855 · 243 enrolled · China
  9. Apr 4, 2018Phase 3 study in Breast NeoplasmsNCT03493854 · 500 enrolled · United States, Argentina, Belgium and more
  10. Apr 5, 2018Phase 2 study in Neoplasms, Unknown PrimaryNCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
  11. Sep 12, 2018Phase 2 study in HER2-Positive Early Breast CancerNCT03674112 · 160 enrolled · United States, Argentina, Brazil and more
  12. Jul 17, 2019Phase 3 study in HER2-positive Early Breast CancerNCT04024462 · 200 enrolled · China
  13. Jan 25, 2022Named pertuzumabINNProposed as its International Nonproprietary Name in WHO's List 126
  14. Jun 8, 2022Phase 3 study in Breast NeoplasmsNCT05415215 · 346 enrolled · Argentina, Bosnia and Herzegovina, Brazil and more
  15. Nov 6, 2026Primary completion moved from 2026-12-31 to 2027-03-28Date moved laterphase 3 · +3 months · NCT02320435

Ahead

  1. Mar 28, 2027Primary completion: phase 3 study in Solid TumorsNCT02320435

TargetBeta

ERBB2 →read by rule
“A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 41 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05415215Breast Neoplasms · Argentina, Bosnia and Herzegovina, Brazil and more3CompletedNov 20, 2024346
NCT04024462HER2-positive Early Breast Cancer · China3CompletedDec 13, 2021200
NCT03674112HER2-Positive Early Breast Cancer · United States, Argentina, Brazil and more2CompletedFeb 24, 2020160
NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more2CompletedFeb 14, 2023529
NCT03493854Breast Neoplasms · United States, Argentina, Belgium and more3CompletedJul 4, 2019500
NCT02896855Breast Neoplasms · China3CompletedJun 27, 2018243
NCT02738970Breast Neoplasms · New Zealand1CompletedMay 31, 201888
NCT02586025Breast Neoplasms · China, Korea, Republic of, Taiwan and more3CompletedOct 23, 2017329
NCT02536339Breast Neoplasms · United States2CompletedMay 1, 201940
NCT02507375Carcinoma, Non-Small-Cell Lung · Belgium, Spain, United Kingdom1CompletedDec 200817
NCT02494596Solid Tumor · Spain, United Kingdom1CompletedSep 200519
NCT02490475Solid Tumor · Netherlands, United Kingdom1CompletedApr 200619
NCT02491892Breast Neoplasms · Australia, Belgium, Finland and more2CompletedApr 200579
NCT02480010Prostatic Neoplasms · France, Germany, Italy and more2TerminatedSep 200568
NCT02445586Breast Neoplasms · India4CompletedSep 26, 201852
NCT02320435Solid Tumors · Brazil, China, Costa Rica and more3Active, not recruitingMar 28, 2027154
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedMay 31, 20191,044
NCT02132949Breast Neoplasms · United States, Canada, Denmark and more2CompletedMar 3, 2016401
NCT02091141Neoplasms · United States2CompletedMay 24, 2023673
NCT02004093Ovarian Neoplasms · Belgium, Canada, Hungary and more2CompletedSep 2008149
NCT01774786Stomach Neoplasms · United States, Australia, Austria and more3CompletedDec 9, 2016780
NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more3CompletedJan 30, 2015208
NCT01674062Breast Neoplasms · Canada, France, Italy and more2CompletedFeb 200895
NCT01572038Breast Neoplasms · Algeria, Argentina, Australia and more3CompletedSep 20, 20191,436
NCT01565083Breast Neoplasms · United States, Brazil, Denmark and more2CompletedOct 2015213
NCT01491737Breast Neoplasms · United States, Brazil, France and more2CompletedMar 17, 2016258
NCT01461057Stomach Neoplasms · Belgium, Czechia, France and more2CompletedMar 1, 201530
NCT01358877Breast Neoplasms · United States, Argentina, Australia and more3CompletedDec 19, 20164,804
NCT01120184Breast Neoplasms · United States, Argentina, Australia and more3CompletedSep 30, 20141,095
NCT01026142Breast Neoplasms · Argentina, Austria, Belgium and more3CompletedMay 29, 2015452
NCT00976989Breast Neoplasms · Bahamas, Bosnia and Herzegovina, Brazil and more2CompletedJun 2011225
NCT00875979Breast Neoplasms · United States, Belgium, Canada and more2CompletedAug 201167
NCT00855894Carcinoma, Non-Small-Cell Lung · United States, Australia2CompletedMar 201241
NCT00567190Breast Neoplasms · United States, Argentina, Brazil and more3CompletedMay 13, 2011808
NCT00545688Breast Neoplasms · Australia, Austria, Brazil and more2CompletedSep 22, 2014417
NCT00096993Ovarian Neoplasms · United States2CompletedSep 2007131
NCT00096941Solid Cancers2CompletedOct 20073
NCT00063154Carcinoma, Non-Small-Cell Lung · United States2CompletedApr 200551
NCT00058552Ovarian Neoplasms2CompletedJul 2004129
NCT00058539Prostatic Neoplasms2CompletedOct 200442
NCT00027027Neoplasms · United States1CompletedAug 200321

How it is read

Names in the registry

  • “Pertuzumab”, 36 entries
  • “Pertuzumab IV”, 4 entries
  • “Perjeta”, 3 entries
  • “pertuzumab”, 2 entries
  • “RhuMab 2C4”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.